18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer

Article Properties
  • Language
    English
  • DOI (url)
    10.2967/jnumed.123.267186
  • Publication Date
    2024/03/21
  • Journal
    Journal of Nuclear Medicine
  • Indian UGC (journal)
  • Refrences
    17
  • Samuel L. Cytryn
  • Neeta Pandit-Taskar
  • Melissa A. Lumish
  • Steven B. Maron
  • Ping Gu
  • Geoffrey Y. Ku
  • Joanne F. Chou
  • Marinela Capanu
  • Ariel Antoine
  • Diane Loegel
  • Lara Feder
  • Steven Philemond
  • Serge K. Lyashchenko
  • Jason S. Lewis
  • Viktoriya Paroder
  • Amitabh Srivastava
  • Laura H. Tang
  • Heiko Schoder
  • Yelena Y. Janjigian
Cite
Cytryn, Samuel L., et al. “18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer”. Journal of Nuclear Medicine, 2024, p. jnumed.123.267186, https://doi.org/10.2967/jnumed.123.267186.
Cytryn, S. L., Pandit-Taskar, N., Lumish, M. A., Maron, S. B., Gu, P., Ku, G. Y., Chou, J. F., Capanu, M., Antoine, A., Loegel, D., Feder, L., Philemond, S., Lyashchenko, S. K., Lewis, J. S., Paroder, V., Srivastava, A., Tang, L. H., Schoder, H., & Janjigian, Y. Y. (2024). 18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer. Journal of Nuclear Medicine, jnumed.123.267186. https://doi.org/10.2967/jnumed.123.267186
Cytryn SL, Pandit-Taskar N, Lumish MA, Maron SB, Gu P, Ku GY, et al. 18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer. Journal of Nuclear Medicine. 2024;:jnumed.123.267186.
Journal Categories
Medicine
Medicine (General)
Medicine
Medicine (General)
Medical physics
Medical radiology
Nuclear medicine
You May Also Like
Refrences
Title Journal Journal Categories Citations Publication Date
The discovery and evaluation of [18F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement European Journal of Nuclear Medicine and Molecular Imaging
  • Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine
  • Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine
  • Medicine: Medicine (General)
  • Medicine: Medicine (General)
 4 2024
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial 2023
High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma Modern Pathology
  • Medicine: Medicine (General): Medical technology
  • Medicine: Pathology
  • Medicine: Medicine (General)
  • Medicine: Medicine (General)
 11 2023
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial The Lancet Oncology
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 2023
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy

 Gastric Cancer
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
  • Medicine: Medicine (General)
 42 2022